Abstract
Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.
Keywords: mitogen-activated (MAP) kinase, cyclic AMP response element binding protein (CREB), ERK Phosphorylation, Monoamine Receptor Agonists, GSK-3 Inhibitors
CNS & Neurological Disorders - Drug Targets
Title: Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
Volume: 6 Issue: 2
Author(s): Keith Q. Tanis, Samuel S. Newton and Ronald S. Duman
Affiliation:
Keywords: mitogen-activated (MAP) kinase, cyclic AMP response element binding protein (CREB), ERK Phosphorylation, Monoamine Receptor Agonists, GSK-3 Inhibitors
Abstract: Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.
Export Options
About this article
Cite this article as:
Tanis Q. Keith, Newton S. Samuel and Duman S. Ronald, Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development, CNS & Neurological Disorders - Drug Targets 2007; 6 (2) . https://dx.doi.org/10.2174/187152707780363276
DOI https://dx.doi.org/10.2174/187152707780363276 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosafety of Onco-Retroviral Vectors
Current Gene Therapy Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study
Anti-Cancer Agents in Medicinal Chemistry Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Supportive-Expressive (SE) Psychotherapy: An Update
Current Psychiatry Reviews Meet Our Editorial Board Member
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Mice with Liver Composed of Human Hepatocytes as an Animal Model for Drug Testing
Current Drug Discovery Technologies Future Developments in Osteoporosis Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Characterization of Mitogen-Activated Protein Kinase Expression in Nucleus Accumbens and Hippocampus of Rats Subjected to Food Selection in the Cafeteria Diet Protocol
CNS & Neurological Disorders - Drug Targets Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design SUMOylation in Neurological Diseases
Current Molecular Medicine Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Virulence Factors of Candida albicans Isolates from the Oral Cavities of HIV-1-Positive Patients
Current HIV Research From Hygiene Hypothesis to Novel Allergic Asthma Therapeutics
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design